Screener
Xeris Biopharma Holdings, Inc. XERS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|
| Accrued returns reserve | (371) | 700 |
| Operating lease liabilities | (911) | (742) |
| Other | 296 | 1,091 |
| Net cash provided by (used in) operating activities | 18,133 | (9,849) |
| Cash flows from investing activities: | ||
| Capital expenditures | (534) | (292) |
| Net cash used in investing activities | (534) | (292) |
| Cash flows from financing activities: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s operating cash flow?
- Xeris Biopharma Holdings, Inc. (XERS) reported operating cash flow of $8.26M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s operating cash flow changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s operating cash flow increased by 4440.1% year-over-year, from $182K to $8.26M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s operating cash flow?
- Over 3 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s operating cash flow has grown at a -33.1% compound annual growth rate (CAGR), from -$95.54M to $28.63M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Xeris Biopharma Holdings, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude